Bookmark
Forward
Explore Literature Results
QuickView for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=DF855E1FCDC082CA178D4759DE591992;jsessionid=CEC07D6E3BD976C0A49BA3484965CE27;jsessionid=CC2B2FF77BE70ED30A59008DC57D82D7;jsessionid=BCDCBA568148BCE772D8C18BD107F409;jsessionid=87BCD66CB73E0442B3535617CE520F90;jsessionid=91E8E26D12F62B649E6AB24F8EBF07B4;jsessionid=23FE0CA14E3489DFC2C4A767D907589D;jsessionid=FAFEA9D99F9A41381F3BCA2C2FB710EC (gene)
Most Relevant Literature
- Computational analysis predicts the Kaposi's sarcoma-associated herpesvirus tegument protein ORF63 t…
- Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma G…
- Stability of varicella-zoster virus open reading frame 63.
- Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons.
- Regions of the varicella-zoster virus open reading frame 63 latency-associated protein important for…
Most Relevant Clinical Trials
There were no clinical trials for TAKL;jsessionid=40E22499564EAE7F71FA29AA19705F76;jsessionid=787005E39F3AFF5E382EC41A340AB170;jsessionid=C367D95CAF574A9239FE4295078310FA;jsessionid=DF855E1FCDC082CA178D4759DE591992;jsessionid=CEC07D6E3BD976C0A49BA3484965CE27;jsessionid=CC2B2FF77BE70ED30A59008DC57D82D7;jsessionid=BCDCBA568148BCE772D8C18BD107F409;jsessionid=87BCD66CB73E0442B3535617CE520F90;jsessionid=91E8E26D12F62B649E6AB24F8EBF07B4;jsessionid=23FE0CA14E3489DFC2C4A767D907589D;jsessionid=FAFEA9D99F9A41381F3BCA2C2FB710EC
Explore Clinical Trials Results
